Advertisement
ETON vs MDGL
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ETON is a StrongBuy and MDGL is a StrongBuy.
ETON's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for ETON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 21 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where ETON advanced for three days, in 243 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ETON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ETON as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
ETON moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ETON crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ETON entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ETON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (30.783) is normal, around the industry mean (8.432). ETON has a moderately high P/E Ratio (109.065) as compared to the industry average of (-1.821). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (15.798) is also within normal values, averaging (178.797).
MDGL in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 42 cases where MDGL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MDGL's RSI Indicator exited the oversold zone, 21 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The 10-day moving average for MDGL crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MDGL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.425) is normal, around the industry mean (2.974). P/E Ratio (-31.475) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ETON | MDGL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 8 | 22 | |
SMR RATING 1..100 | 28 | 98 | |
PRICE GROWTH RATING 1..100 | 35 | 63 | |
P/E GROWTH RATING 1..100 | 20 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDGL's Valuation (16) in the Pharmaceuticals Other industry is significantly better than the same rating for ETON (89) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew significantly faster than ETON’s over the last 12 months.
ETON's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is in the same range as MDGL (22) in the Pharmaceuticals Other industry. This means that ETON’s stock grew similarly to MDGL’s over the last 12 months.
ETON's SMR Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for MDGL (98) in the Pharmaceuticals Other industry. This means that ETON’s stock grew significantly faster than MDGL’s over the last 12 months.
ETON's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as MDGL (63) in the Pharmaceuticals Other industry. This means that ETON’s stock grew similarly to MDGL’s over the last 12 months.
ETON's P/E Growth Rating (20) in the Pharmaceuticals Major industry is in the same range as MDGL (22) in the Pharmaceuticals Other industry. This means that ETON’s stock grew similarly to MDGL’s over the last 12 months.
| ETON | MDGL | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 80% | N/A |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 77% |
| Advances ODDS (%) | 1 day ago 84% | 1 day ago 75% |
| Declines ODDS (%) | 9 days ago 79% | 5 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ETON’s FA Score shows that 3 FA rating(s) are green while MDGL’s FA Score has 3 green FA rating(s).
- ETON’s FA Score: 3 green, 2 red.
- MDGL’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ETON’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).
- ETON’s TA Score: 4 bullish, 5 bearish.
- MDGL’s TA Score: 4 bullish, 3 bearish.
Price Growth
ETON (@Pharmaceuticals: Generic) experienced а +1.93% price change this week, while MDGL (@Biotechnology) price change was -5.82% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.92%. For the same industry, the average monthly price growth was -10.60%, and the average quarterly price growth was +6.14%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.36%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -14.28%.
Reported Earning Dates
ETON is expected to report earnings on Nov 05, 2026.
MDGL is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.92% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-1.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CVLC | 94.96 | 0.70 | +0.74% |
| Calvert US Large-Cap Core Responsible Index ETF (CVLC) | |||
| TSEP | 25.67 | 0.19 | +0.74% |
| FT Vest Emerging Market Buffer ETF - September (TSEP) | |||
| JULW | 41.75 | 0.16 | +0.38% |
| AllianzIM U.S. Equity Buffer20 Jul ETF (JULW) | |||
| BNDX | 47.29 | 0.05 | +0.11% |
| Vanguard Total International Bond ETF (BNDX) | |||
| CEV | 10.35 | -0.05 | -0.48% |
| Eaton Vance California Municipal Income Trust | |||